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Tuberculosis (TB) remains an infectious disease of worldwide concern. Therapeuticdrug monitoring (TDM) of blood could be helpful in optimizing TB treatment, as
anti-TB drug exposure shows interpatient variability (1). TDM in saliva instead of blood
is currently being studied as a more practical alternative, since saliva sampling is
noninvasive and more acceptable to patients (2, 3). Along with the growing interest in
the pharmacokinetics of anti-TB drugs, TDM is increasingly used in daily routine
practice. However, the saliva of infectious TB patients contains Mycobacterium tuber-
culosis and TDM sample analysis usually does not take place in a biosafety level 3
laboratory. A quantitative study found a mean bacterial load of 7 104 (range, 1 102
to 6  105) CFU/ml in the saliva of infectious TB patients (4). Laboratory-acquired TB
infections should be prevented by applying biosafety measures when working with M.
tuberculosis-containing saliva samples (5). Therefore, saliva samples from TB patients
require sterilization prior to laboratory processing (e.g., centrifugation). Unfortunately,
heat sterilization is not possible because of the thermal instability of drugs. The
objective of this experiment was to test whether membrane ﬁltration is able to reliably
decontaminate a solution containing M. tuberculosis.
Five M. tuberculosis strains (Table 1) were incubated in Mycobacteria Growth Indi-
cator Tubes (MGITs; Becton, Dickinson and Company, United States) after the addition
of 0.8 ml of oleic acid, albumin, dextrose, and catalase as a growth supplement. For
each strain, 2.0 ml of culture ﬂuid containing at least 105 to 106 CFU/ml was ﬁltered in
duplicate with a polyvinylidene ﬂuoride membrane ﬁlter with a pore size of 0.22 m
and a diameter of 33 mm (Millex-GV; Merck Millipore, Ireland). The ﬁltrate was inocu-
lated into a new MGIT with culture ﬂuid. For each strain, 0.5 ml of culture ﬂuid
containing at least 105 to 106 CFU/ml was also inoculated into a new MGIT as a positive
control. All tubes were incubated at 36.5°C for 55 days in the Bactec MGIT 960 system
(Becton, Dickinson and Company, United States). No mycobacterial growth was ob-
served in the MGITs inoculated with ﬁltrate, while all of the control tubes were positive
within 2 weeks (Table 1).
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This is the ﬁrst description of membrane ﬁltration ofM. tuberculosis-containing ﬂuids
for sterilization in the process of TDM. No mycobacterial growth was measured in any
of the ﬁltrates. The membrane ﬁlter therefore successfully ﬁltered all of the bacteria of
multiple M. tuberculosis strains from culture ﬂuids. We found no difference among the
ﬁve strains in the number of growth units in the ﬁltrates. It is not possible to test all of
the M. tuberculosis isolates received at a mycobacterial laboratory, but according to this
experiment, variation in the feasibility of membrane ﬁltration between different strains
is not likely. Membrane ﬁltration of solutions with a larger bacterial load than that
tested here requires further investigation, as sterilization cannot be ensured by only this
experiment. However, the bacterial load in saliva from TB patients is usually not as large
as that tested in this experiment (4). Because of the satisfying results obtained with
culture ﬂuids with large bacterial loads, we conclude that membrane ﬁltration is
suitable for the decontamination of salivary TDM samples from infectious TB patients.
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No. of growth units
Positive
control Filtrate A Filtrate B
1 M. tuberculosis complex Sensitive 7,037 0 0
2 M. tuberculosis Isoniazid, rifampin 18,216 0 0
3 M. tuberculosis Rifampin 20,413 0 0
4 M. tuberculosis Sensitive 26,757 0 0
H37Rv M. tuberculosis Sensitive 22,776 0 0
aIn duplicate (A and B).
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